

cine), while established fields of social science are being redefined as new medical subspecialties—developmental psychology is becoming behavioral pediatrics and community pediatrics (1). This results in physicians being removed from the delivery of medical care, where there is an apparent shortage of such manpower, to administer social science research and evaluation, for which physicians require additional training. Thus, society pays physicians' salaries to reduce and restrain a scarce manpower pool, while the applied social sciences suffer from an oversupply of manpower similar to that of the engineering sciences.

EDWARD N. PETERS

Department of Pediatrics,
University of Rochester,
Rochester, New York 14642

References

1. A. F. North, *Clin. Pediat.* **8**, 1 (1969).

I certainly agree that I primarily presented the viewpoint of the developmental technologist (obviously a very frustrated technologist) without presenting an overall picture of the involvement of other elements essential to health care delivery. As mentioned in the article, the excellent presentation by Schwartz (1) puts these elements in better perspective. But even with the most optimum organizational mode and the best political solutions, all sections of our very heterogeneous society could not achieve and maintain an equally high level of health care delivery with existing technology. For example, much of the technology developed for the relatively large medical centers (most technological developments have been for this area) are not usable with a dispersed population such as that found in Appalachia or in remote areas in the southwestern United States, even if you could convince a sufficient number of health care personnel to serve those areas. Thus, the persistence of inequities among some population subgroups has resulted because of lack of technology. Also, as new advances occur in biomedical research, it would be fortuitous indeed if current technology alone could be used to ensure ultimate application to health care delivery.

As the social sciences become more extensively used in organizing our health care delivery effort, I hope that responsiveness to the needs of the individual will be considered as important as the operational efficiency of the sys-

tem. Perhaps social scientists would be better equipped than physicians to objectively use both of these criteria.

CHARLES D. SCOTT

Biomedical Technology Section,
Oak Ridge National Laboratory,
Oak Ridge, Tennessee 37830

References

1. W. B. Schwartz, *Science* **177**, 967 (1972).

Safety and Efficacy of New Drugs

In the letter from C. Joseph Stetler of the Pharmaceutical Manufacturers Association (12 Jan., p. 127) taking issue with Muller's article (5 May 1972, p. 488) on the socioeconomic of drug therapy and the "overmedicated society," there is the oft-repeated rebuttal that "Advertising claims [for drugs] must be based upon FDA-approved labeling. . . ." This is a continual excuse by those in the drug industry to imply that all drugs on the market are both safe and efficacious. But this is simply not true. Drugs are still being advertised and sold that have not received FDA (Food and Drug Administration) approval (1). The following are excerpts from letters to me from D. N. Kilburn (2) of the FDA concerning Lipo-K, a drug that has been seized several times by the FDA since 1967 because it was shipped in interstate commerce without an approved new drug application.

. . . In our opinion, the Lipo-K capsule is a new drug subject to the new drug provisions of the [Federal Food, Drug and Cosmetic] Act. However, Marcen Laboratories, Inc., has not submitted a new-drug application to us pursuant to the new drug provisions of the Act.

. . . Despite a court order decreeing that each of the drugs seized in a legal action, including Lipo-K capsules, is a new drug without an approved new drug application. . . [u]ntil the determination of the new drug status of Lipo-K products has been finalized and as long as the products are marketed, they may be advertised.

Thus drugs for which claims have not been approved by the FDA may still be advertised and sold.

EDWARD R. PINCKNEY

Box P,
Beverly Hills, California 90213

References

1. U.S. Senate, Subcommittee on Monopoly, "Competitive problems in the drug industry," *Hearings before the U.S. Senate Subcommittee on Monopoly, Part 14* (Government Printing Office, Washington, D.C., 1969), p. 5723.
2. D. N. Kilburn, personal communications.

Raven Press

15 West 84th St., New York City 10024

ADVANCES IN CYCLIC NUCLEOTIDE RESEARCH, VOL. 3

Series Editors: P. Greengard and G.A. Robison. Six major review articles covering crucial topics in the field. 1. Adenyl cyclase, by J.P. Perkins. 2. Phosphodiesterases, by M. Appleman et al. 3. Protein kinase substrates, by T.A. Langan. 4. Cyclic GMP, by N. Goldberg. 5. Derivatives of cyclic nucleotides, by L.N. Simon et al. 6. Clinical aspects, by F. Murad. 378 pp., \$17.95

ADVANCES IN CYCLIC NUCLEOTIDE RESEARCH, VOL. 2: New Assay Methods for Cyclic Nucleotides

Volume Editors: P. Greengard, R. Paoletti and G.A. Robison. "The volume is a handbook of cyclic nucleotide methodology and should be read by any investigator who seriously chooses to study the effects of cyclic nucleotides or measure the concentrations of cyclic nucleotides in tissues and fluids... an indispensable book to serious investigators in the field." -*CLINICAL CHEMISTRY*. 145 pp., \$12.50

POLYAMINES IN NORMAL AND NEOPLASTIC GROWTH

Edited by D.H. Russell. A National Cancer Institute Monograph. This volume details the role of polyamines in the regulation of cellular differentiation, protein and nucleic acid synthesis, hormonal responses, and many other areas of cell growth and development. Recent evidence indicates that determinations of polyamine levels in body fluids can serve as a sensitive means of detecting malignant growth. 435 pp., \$21.50

CHOLINE AND ACETYLCHOLINE: HANDBOOK OF CHEMICAL ASSAY METHODS

Edited by I. Hanin. Incorporates into a single volume 14 sensitive working methods for the chemical microassay of acetylcholine and/or choline which rival bioassay in limit of sensitivity. 200 pp., \$15.95

GAS CHROMATOGRAPHY-MASS SPECTROMETRY IN NEUROBIOLOGY

Edited by E. Costa and B. Holmstedt. The chapters in this volume cover a variety of instruments and a wide range of topics, showing the power of the method in detecting minute amounts of drugs and endogenous substances, as well as in determining chemical structures. 200 pp., \$15.95

MONOAMINE OXIDASES-NEW VISTAS

Edited by E. Costa and M. Sandler. "This is a well-organized and properly edited volume which lucidly communicates detailed information about a new generation of monoamine oxidases... a real contribution to the existing body of knowledge about MAO and MAOI..." -*AMERICAN JOURNAL OF PHARMACEUTICAL EDUCATION*. 445 pp., \$19.75

DIETARY LIPIDS AND POST-NATAL DEVELOPMENT

Edited by C. Galli, G. Jacini and A. Pecile. Details the nutritional requirements and biological roles of dietary lipids during early stages of postnatal development in mammals and especially in man. 285 pp., \$17.50

Circle No. 106 on Readers' Service Card